Our findings suggest that the miR-21 could be a potentially useful marker for the prediction of the clinical response to the IFN-α/5-FU combination therapy, and that the miR-21 may serve as a potential target for HCC therapy. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.